Oxford Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Oxford Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-43,160	Closed	-$4.58M	–	920
2019 Q4	$4.58M	Sell	43,160 -10,147	-19%	-$1.07M	0.13%	175
2019 Q3	$5.64M	Sell	53,307 -2,500	-4%	-$262K	0.14%	188
2019 Q2	$5.87M	Hold	55,807	–	–	0.13%	186
2019 Q1	$5.78M	Buy	55,807 +11,043	+25%	+$1.13M	0.13%	182
2018 Q4	$4.57M	Hold	44,764	–	–	0.12%	192
2018 Q3	$4.47M	Buy	44,764 +3,500	+8%	+$348K	0.09%	258
2018 Q2	$4.09M	Buy	41,264 +12,764	+45%	+$1.26M	0.08%	279
2018 Q1	$2.78M	Buy	28,500 +7,500	+36%	+$731K	0.06%	410
2017 Q4	$2.03M	Buy	+21,000	New	+$2.03M	0.04%	562

Other funds holding NRXP

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCM

Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Oxford Asset Management's NRXP Position: Q1 2020 in Review

Oxford Asset Management sold out of NRX Pharmaceuticals (NRXP) in Q1 2020, closing a stake of 43,160 shares — an estimated $4.58M sold.

Oxford Asset Management first reported a position in NRXP in Q4 2017 and held it in 9 quarters. The position peaked at $5.87M in Q2 2019. 7 funds tracked by Wall St. Rank hold NRXP as of Q1 2020.

Oxford Asset Management reported no remaining NRX Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 43,160 NRX Pharmaceuticals shares in Q1 2020, an estimated $4.58M.
Oxford Asset Management first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Oxford Asset Management's NRX Pharmaceuticals position peaked at $5.87M in Q2 2019.
7 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.